Allied(OTC) ALID

Allied Corp. specializes in the research, development, and production of cannabinoid health solutions, primarily operating in the United States. The company markets a diverse portfolio of natural health products derived from hemp under various brands.

Products and Services

• Offers a range of cannabinoid health solutions, including CBD tinctures and gummies
• Features specialized skincare products under the "MaXXa" brand
• Engaged in pharmaceutical development with experimental drug candidates for PTSD

Growth Outlook

• Recent quarterly revenue of $2,471 indicates potential for recovery
• Continued investment in R&D may enhance product offerings and market reach
• Expansion into pharmaceutical development could diversify revenue streams

Financial Highlights

• Trailing twelve months (TTM) revenue of $2,471 shows early signs of growth
• Net income for Q4 2023 reported at -$5,135,789, reflecting ongoing challenges
• Cash and cash equivalents increased to $209,736 in Q4 2023, indicating improved liquidity

Allied Corp. operates in the healthcare sector, focusing on cannabinoid-based products that cater to a growing market for natural health solutions. The company's diverse product lines, including its Tactical Relief and Equilibrium Bio brands, position it well within the expanding wellness industry. Recent financial data indicates a revenue of $2,471 for the most recent quarter, suggesting a potential turnaround after previous challenges. Despite reporting a net loss of $5,135,789 in Q4 2023, the increase in cash reserves to $209,736 reflects improved liquidity, which may support future operations and growth initiatives. The ongoing investment in research and development, particularly in pharmaceutical applications, could further enhance the company's market position and revenue potential. Overall, Allied Corp. presents an intriguing opportunity for investors interested in the cannabinoid health solutions market, with a focus on innovation and product diversification.